Edition:
United States

MannKind Corp (MNKD.OQ)

MNKD.OQ on NASDAQ Stock Exchange Global Market

3.04USD
23 Feb 2018
Change (% chg)

$0.06 (+2.01%)
Prev Close
$2.98
Open
$3.06
Day's High
$3.13
Day's Low
$2.99
Volume
516,414
Avg. Vol
906,453
52-wk High
$6.96
52-wk Low
$0.67

Latest Key Developments (Source: Significant Developments)

Mannkind, On Jan 18, Co, Unit Entered Into Exchange, Sixth Amendment To Facility Agreement With Deerfield
Friday, 19 Jan 2018 07:02am EST 

Jan 19 (Reuters) - Mannkind Corp ::MANNKIND - ‍ ON JAN 18, CO AND UNIT ENTERED INTO AN EXCHANGE AND SIXTH AMENDMENT TO FACILITY AGREEMENT WITH DEERFIELD - SEC FILING​.MANNKIND CORP - ‍ PURSUANT TO AMENDMENT, CO AGREED TO ISSUE TO DEERFIELD AGGREGATE OF 1.3 MILLION SHARES OF ITS STOCK, PAR VALUE $0.01 PER SHARE.MANNKIND - ‍ TO ISSUE TO DEERFIELD AGGREGATE OF 1.3 MILLION SHARES OF ITS STOCK, PAR VALUE $0.01 PER SHARE IN EXCHANGE FOR $3.2 MILLION OF TRANCHE 4 NOTES​.MANNKIND CORP SAYS PAYMENT DATE FOR REMAINING $1.25 MILLION IN REMAINING PRINCIPAL AMOUNT OF TRANCHE 4 NOTES WAS EXTENDED TO MAY 6, 2018.MANNKIND CORP - CO ALSO ENTERED INTO SECOND AMENDMENT TO ESCROW AGREEMENT, DATED JAN 18, 2018, WITH DEERFIELD AND US BANK,.MANNKIND - ‍ PURSUANT TO AMENDMENT TO ESCROW AGREEMENT, PARTIES EXTENDED PERIOD OF ESCROW ESTABLISHED THEREUNDER TO MAY 6, 2018.  Full Article

Mannkind Q3 loss per share $0.31
Tuesday, 7 Nov 2017 04:01pm EST 

Nov 7 (Reuters) - Mannkind Corp ::Mannkind Corporation reports 2017 third quarter financial results.Q3 loss per share $0.31.  Full Article

Mannkind restructures near-term debt obligations
Monday, 23 Oct 2017 08:00am EDT 

Oct 23 (Reuters) - Mannkind Corp ::Mannkind restructures near-term debt obligations.Mannkind Corp - ‍extended maturity of $10 million of deerfield facility to Jan 15, 2018 and allowed for such principal to be converted into common stock​.Mannkind - ‍new 5.75 pct convertible senior subordinated exchange notes due 2021, common stock to be issued.Mannkind - ‍new 5.75 pct notes due 2021, common stock to be issued in exchange for existing convertible senior subordinated exchange notes due 2018​.Mannkind - ‍2021 notes will bear interest at rate of 5.75 pct per year on principal amount, payable semiannually​.Mannkind - ‍2021 notes will mature on october 23, 2021​.Mannkind - facility agreement amended to provide that deerfield may convert principal due into aggregate of up to 4 million shares of co's stock​.  Full Article

Mannkind and Biomm submit registration dossier to Brazilian Health Regulatory Agency (anvisa)
Monday, 23 Oct 2017 07:00am EDT 

Oct 23 (Reuters) - Biomm Sa ::Mannkind and Biomm submit registration dossier to Brazilian Health Regulatory Agency (anvisa).Mannkind Corp - co, Biomm SA announce submission of registration dossier to anvisa, seeking approval of afrezza inhalation powder in Brazil​.  Full Article

Mannkind Corp says FDA updates Afrezza prescribing information
Monday, 2 Oct 2017 06:00am EDT 

Oct 2 (Reuters) - Mannkind Corp ::FDA updates Afrezza® prescribing information.Says ‍U.S. FDA has approved an update to Afrezza prescribing information​.Mannkind Corp - ‍U.S. FDA has approved an update to Afrezza prescribing information to include new clinical data​.Says ‍label update includes study data that describe time-action profile by dosage strength​.  Full Article

MannKind says Raymond Urbanski, co's chief medical officer, informed co of his decision to resign​
Monday, 11 Sep 2017 08:50am EDT 

Sept 11 (Reuters) - Mannkind Corp :MannKind - On Sept 8, Raymond Urbanski, co's chief medical officer, informed co of his decision to resign effective Sept 29, 2017 - SEC filing​.MannKind Corp - ‍Urbanski is resigning in order to "pursue his passion" for oncology at another company​.  Full Article

Mannkind says delivered written certification to Deerfield Private Design Fund II LP, others certifying extension conditions of facility deal were met​
Wednesday, 6 Sep 2017 04:49pm EDT 

Sept 6 (Reuters) - Mannkind Corp :Mannkind-On Aug 31,delivered written certification to Deerfield Private Design Fund II, L.P, others certifying extension conditions of facility deal were met​.Mannkind - ‍in connection with certificate, co elected to defer payment of principal on tranche 4 notes from Aug 31, 2017 to Oct 31, 2017 - SEC Filing​.Mannkind- ‍per terms of Deerfield amendment, co's obligation under agreement to maintain at least $25 million in cash as of each quarter end reduced to $10 million​.  Full Article

Mannkind Corp resolved to voluntary delist from Tel Aviv Stock Exchange Ltd
Monday, 7 Aug 2017 04:10pm EDT 

Aug 7 (Reuters) - Mannkind Corp :Mannkind corp - ‍on august 4, board resolved to voluntary delist its common stock from tel aviv stock exchange ltd - sec filing​.Mannkind corp - ‍delisting of mannkind's common stock from trading on tase is expected to become effective three months from date of request​.  Full Article

MannKind Corporation reports 2017 second quarter financial results
Monday, 7 Aug 2017 04:05pm EDT 

Aug 7 (Reuters) - Mannkind Corp :Q2 loss per share $0.35.Q2 revenue $2.2 million.  Full Article

MannKind and One Drop partner to launch the A-one clinical trial
Monday, 7 Aug 2017 06:30am EDT 

Aug 7 (Reuters) - MannKind Corp :MannKind and One Drop partner to launch the A-one clinical trial.MannKind Corp - Collaboration with launch of A-one study.MannKind - A-one study, is randomized controlled trial investigating use of Afrezza inhaled insulin, One Drop's integrated digital diabetes care platform.  Full Article

BRIEF-David Kendall Joins MannKind As Chief Medical Officer

* MANNKIND CORP - MOST RECENTLY, KENDALL SERVED AS RESEARCH PHYSICIAN AND VICE PRESIDENT OF GLOBAL MEDICAL AFFAIRS FOR LILLY DIABETES​ Source text for Eikon: Further company coverage: